Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT)

By D. Bänsch, M. Antz, S. Boczor, M. Volkmer, J. Tebbenjohanns, K. Seidl, M. Block, F. Gietzen, J. Berger, K. Kuck. Circulation, 2002

687 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, neutral): “Data on the role of the ICD in patients with non-ischaemic dilated cardiomyopathy (DCM) are more limited.(164) –166 The SCD-HeFT trial(157) enrolled patients with both DCM and ischaemic LV dysfunction, and showed a 23% reduction in mortality.”
ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. (2008, methodology): “The study was terminated before the primary end point was reached because of a lower-than-expected incidence of all-cause mortality (377).”
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, methodology): “ICD therapy did not improve the survival of patients with HF due to nonischemic DCM in 2 small trials.(635,645) However, the SCD-HeFT trial demonstrated a 23% reduction in total mortality with ICD treatment in comparison to placebo.”